Cargando…

Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo

Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Imanishi, Ichiro, Uchiyama, Jumpei, Tsukui, Toshihiro, Hisatsune, Junzo, Ide, Kaori, Matsuzaki, Shigenobu, Sugai, Motoyuki, Nishifuji, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784202/
https://www.ncbi.nlm.nih.gov/pubmed/31443379
http://dx.doi.org/10.3390/v11090769
_version_ 1783457715607044096
author Imanishi, Ichiro
Uchiyama, Jumpei
Tsukui, Toshihiro
Hisatsune, Junzo
Ide, Kaori
Matsuzaki, Shigenobu
Sugai, Motoyuki
Nishifuji, Koji
author_facet Imanishi, Ichiro
Uchiyama, Jumpei
Tsukui, Toshihiro
Hisatsune, Junzo
Ide, Kaori
Matsuzaki, Shigenobu
Sugai, Motoyuki
Nishifuji, Koji
author_sort Imanishi, Ichiro
collection PubMed
description Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the target bacteria without disturbance of the normal microflora. In this study, we investigated the therapeutic potential of a recombinant endolysin derived from kayvirus S25-3 against staphylococcal impetigo in an experimental setting. First, the recombinant S25-3 endolysin required an incubation period of over 15 minutes to exhibit efficient bactericidal effects against S. aureus. Second, topical application of the recombinant S25-3 endolysin decreased the number of intraepidermal staphylococci and the size of pustules in an experimental mouse model of impetigo. Third, treatment with the recombinant S25-3 endolysin increased the diversity of the skin microbiota in the same mice. Finally, we revealed the genus-specific bacteriolytic effect of recombinant S25-3 endolysin against staphylococci, particularly S. aureus, among human skin commensal bacteria. Therefore, topical treatment with recombinant S25-3 endolysin can be a promising disease management procedure for staphylococcal impetigo by efficient bacteriolysis of S. aureus while improving the cutaneous bacterial microflora.
format Online
Article
Text
id pubmed-6784202
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67842022019-10-16 Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo Imanishi, Ichiro Uchiyama, Jumpei Tsukui, Toshihiro Hisatsune, Junzo Ide, Kaori Matsuzaki, Shigenobu Sugai, Motoyuki Nishifuji, Koji Viruses Article Impetigo is a contagious skin infection predominantly caused by Staphylococcus aureus. Decontamination of S. aureus from the skin is becoming more difficult because of the emergence of antibiotic-resistant strains. Bacteriophage endolysins are less likely to invoke resistance and can eliminate the target bacteria without disturbance of the normal microflora. In this study, we investigated the therapeutic potential of a recombinant endolysin derived from kayvirus S25-3 against staphylococcal impetigo in an experimental setting. First, the recombinant S25-3 endolysin required an incubation period of over 15 minutes to exhibit efficient bactericidal effects against S. aureus. Second, topical application of the recombinant S25-3 endolysin decreased the number of intraepidermal staphylococci and the size of pustules in an experimental mouse model of impetigo. Third, treatment with the recombinant S25-3 endolysin increased the diversity of the skin microbiota in the same mice. Finally, we revealed the genus-specific bacteriolytic effect of recombinant S25-3 endolysin against staphylococci, particularly S. aureus, among human skin commensal bacteria. Therefore, topical treatment with recombinant S25-3 endolysin can be a promising disease management procedure for staphylococcal impetigo by efficient bacteriolysis of S. aureus while improving the cutaneous bacterial microflora. MDPI 2019-08-22 /pmc/articles/PMC6784202/ /pubmed/31443379 http://dx.doi.org/10.3390/v11090769 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Imanishi, Ichiro
Uchiyama, Jumpei
Tsukui, Toshihiro
Hisatsune, Junzo
Ide, Kaori
Matsuzaki, Shigenobu
Sugai, Motoyuki
Nishifuji, Koji
Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title_full Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title_fullStr Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title_full_unstemmed Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title_short Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo
title_sort therapeutic potential of an endolysin derived from kayvirus s25-3 for staphylococcal impetigo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784202/
https://www.ncbi.nlm.nih.gov/pubmed/31443379
http://dx.doi.org/10.3390/v11090769
work_keys_str_mv AT imanishiichiro therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT uchiyamajumpei therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT tsukuitoshihiro therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT hisatsunejunzo therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT idekaori therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT matsuzakishigenobu therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT sugaimotoyuki therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo
AT nishifujikoji therapeuticpotentialofanendolysinderivedfromkayviruss253forstaphylococcalimpetigo